LON:ARIX - Arix Bioscience Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 147.50 0.00 (0.00 %) (As of 05/23/2019 04:00 PM ET)Previous CloseGBX 147.50Today's RangeGBX 145.10 - GBX 146.4052-Week RangeGBX 137 - GBX 209.50Volume7,095 shsAverage Volume65,433 shsMarket Capitalization£185.13 millionP/E Ratio5.14Dividend YieldN/ABetaN/A ProfileAnalyst RatingsChartInsider TradesHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Arix Bioscience plc, formerly known as Perceptive Bioscience Investments Limited, is a venture capital firm specializing in seed, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, medical innovation comprising healthcare and life sciences. It seeks to invest globally. The firm employs an evergreen approach to funding. It primarily makes investments from its own balance sheet. The firm prefers to take board seat. The firm exit when the optimum value has been reached. Arix Bioscience plc is based in London, United Kingdom with an additional office in New York, New York. Receive ARIX News and Ratings via Email Sign-up to receive the latest news and ratings for ARIX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:ARIX Previous Symbol CUSIPN/A CIKN/A Webhttp://arixbioscience.com/ Phone+44-20-72901050Debt Debt-to-Equity RatioN/A Current Ratio10.06 Quick Ratio10.02Price-To-Earnings Trailing P/E Ratio5.14 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£52.50 million Price / Sales3.53 Cash FlowGBX 71.60 per share Price / Cash Flow2.06 Book ValueGBX 212.10 per share Price / Book0.70Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees14 Outstanding Shares125,515,000Market Cap£185.13 million Next Earnings DateN/A OptionableNot Optionable Arix Bioscience (LON:ARIX) Frequently Asked Questions What is Arix Bioscience's stock symbol? Arix Bioscience trades on the London Stock Exchange (LON) under the ticker symbol "ARIX." What price target have analysts set for ARIX? 2 Wall Street analysts have issued 12 month target prices for Arix Bioscience's shares. Their predictions range from GBX 270 to GBX 270. On average, they anticipate Arix Bioscience's share price to reach GBX 270 in the next year. This suggests a possible upside of 83.1% from the stock's current price. View Analyst Price Targets for Arix Bioscience. What is the consensus analysts' recommendation for Arix Bioscience? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arix Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arix Bioscience. Has Arix Bioscience been receiving favorable news coverage? Media headlines about ARIX stock have been trending somewhat positive on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Arix Bioscience earned a daily sentiment score of 1.9 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. Who are some of Arix Bioscience's key competitors? Some companies that are related to Arix Bioscience include Mesoblast (MSB), Polynovo (PNV), Resverlogix (RVX), Emerald Health Therapeutics (EMH), Starpharma (SPL), Biotest (BIO), Oxford BioMedica (OXB), Neptune Wellness Solutions (NEPT), Theratechnologies (TH), Senesco Technologies (ELOX), Kodiak Sciences (KOD), OncoCyte (OCX), IMV (IMV), Paradigm Biopharmaceuticals (PAR) and Monash IVF Group (MVF). Who are Arix Bioscience's key executives? Arix Bioscience's management team includes the folowing people: Dr. Joseph Anderson, CEO & Co-Founder (Age 60)Mr. James Hedley Rawlingson, Chief Financial Officer (Age 51)Sir Christopher Thomas Evans, Consultant (Age 62)Mr. Robert Lyne, COO, Gen. Counsel & Company Sec.Ms. Charlotte Parry, Head of Investor Relations How do I buy shares of Arix Bioscience? Shares of ARIX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Arix Bioscience's stock price today? One share of ARIX stock can currently be purchased for approximately GBX 147.50. How big of a company is Arix Bioscience? Arix Bioscience has a market capitalization of £185.13 million and generates £52.50 million in revenue each year. Arix Bioscience employs 14 workers across the globe. What is Arix Bioscience's official website? The official website for Arix Bioscience is http://arixbioscience.com/. How can I contact Arix Bioscience? Arix Bioscience's mailing address is 20 Berkeley Square, LONDON, W1J 6EQ, United Kingdom. The company can be reached via phone at +44-20-72901050. MarketBeat Community Rating for Arix Bioscience (LON ARIX)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 62 (Vote Outperform)Underperform Votes: 76 (Vote Underperform)Total Votes: 138MarketBeat's community ratings are surveys of what our community members think about Arix Bioscience and other stocks. Vote "Outperform" if you believe ARIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARIX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/23/2019 by MarketBeat.com StaffFeatured Article: Institutional Investors Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.